| P13 | Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment | Charles W. Abbott, III, PhD; Sean M. Boyle, PhD; Eric Levy, PhD; Rena McClory; Sekwon Jang, MD; Richard Chen | Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Neoantigens; Tumor evasion; Tumor microenvironment |
| P14 | Durvalumab treatment-induced transcriptional changes in the tumor microenvironment associated with longer survival in patients with late stage Non-Small Cell Lung Cancer (NSCLC) | Ikbel Achour, PhD; Zachary A. Cooper, PhD; Sriram Sridhar; Maria L. Ascierto, PhD; Jixin Wang; Young S. Lee; Natasha Angra; Shaad E. Abedin, MD, FACP; Rajiv G. Raja, PhD; Brandon W. Higgs, PhD; Maria Jure-Kunkel | B cell; Biomarkers; Checkpoint blockade; Dendritic cell; Gene expression; Immune contexture; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P15 | Development of a Robust, Simplified Method to Measure Receptor Occupancy in Peripheral Blood from Patients Treated with a Novel Anti-PD-1 Agent, AB122 | Devika Ashok, PhD; Dana Piovesan, MSc; Sharon Zhao; Hema Singh; Steve W. Young, PhD; Matthew J. Walters, PhD; Lisa Seitz, MSc | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Solid tumors; T cell |
| P16 | Better efficacy of PD-1 antibody predicted by immune-related adverse effects is impaired by high dose steroids | Xue Bai, MD; Michelle Kim; Gyulnara Kasumova; Tatyana Sharova; Justine V. Cohen, DO; Donald Lawrence, MD; Christine Freedman, RN; Riley Fadden, NP; Krista M. Rubin, MS, FNP-BC; Ryan J. Sullivan, MD; Keith T. Flaherty; Genevieve M. Boland, MD, PhD; | Biomarkers; Checkpoint blockade; Clinical study; Immune suppression; Immune toxicity |
| P17 | Combined MAGE-A1,3/6,4, and 10 expression levels quantified in solid tumors by (BaseScope™) RNA in situ hybridization (ISH) identify targets for immunotherapy | Anshika Bajaj, PhD; Helly Xiao Yan Pimentel; Bingqing Zhang, PhD; Ruby Hsu, PhD; Peter Berglund, PhD; Jan H. Ter Meulen, MD, PhD | Adoptive immunotherapy; Biomarkers; Dendritic cell; Gene expression; Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| P18 | Preliminary Evaluation of a Novel Whole Slide Multispectral Assessment of Seven Markers: Potential to Minimize Bias in the Characterization of the Tumor Immune Environment | Carmen Ballesteros Merino, PhD; Shawn M. Jensen, PhD; Carla Coltharp, PhD; Kristin Roman, MS; Chichung Wang; Nikhil Lonberg, HSDG; Sebastian Marwitz; Tarsem L. Moudgil, MS; William L. Miller, BS; William L. Redmond, PhD; Yoshinobu Koguchi, MD, PhD; Carlo B. Bifulco, MD; Clifford C. Hoyt, MS; Bernard A. Fox, PhD | Biomarkers; Immune contexture; Immune monitoring; Immunoscore; Tumor microenvironment; Tumor stroma |
| P19 | Molecular determinants of response to PD-L1 blockade across tumor types | Romain Banchereau; Ning Leng; Edward E. Kadel, III, BS; Dorothee Nickles, PhD; Steve Lianoglou, BS, MSc, PhD; Oliver Zill; Sushit Jhunjhunwala; Luciana Molinero, PhD; Mahrukh Huseni; Marcin Kowanetz, Ph.D.; Richard Bourgon, BS, PhD; Craig Cummings, PhD; Sanjeev Mariathasan, PhD; Priti S. Hegde, PhD; Thomas Powles, MBBS, MD, MRCP | Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Systems biology |
| P20 | A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging | Leeat Keren; Marc Bosse; Robert West; Sean C. Bendall, PhD; Michael Angelo, MD, PhD; | Bioinformatics; Biomarkers; Checkpoint blockade; Immune tolerance; Proteomics; Systems biology; Tumor microenvironment |
| P21 | Deep learning-based PD-L1 tumor cell (TC) scoring improves survival prediction compared to pathologists on durvalumab-treated NSCLC patients | Nicolas Brieu, PhD; Ansh Kapil; Aleksandra Zuraw, Dr.; Supporting Author - Abraham Silva, MD; Supporting Author - Marlon C. Rebelatto, DVM, PhD, DACVP; Supporting Author - Keith E. Steele, DVM, PhD; Presenting Author - Guenter Schmidt, PhD; | Bioinformatics; Biomarkers; Checkpoint blockade |
| P22 | Impact of tumor inherent interferons on immune reactivity and personalized therapy in triple negative breast cancer | Natasha K. Brockwell, BBiomed (Hons); Jai Rautela; Tim Molloy, PhD; Sandra O'Toole, MD, PhD; Vinod Ganju, MBBS, FRACP; Belinda S. Parker; | Biomarkers; Checkpoint blockade; Chemotherapy; Immune contexture; Immune monitoring; Immunoscore; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment; Tumor stroma |
| P23 | Centrifuge-less immunostaining of suspension cells for flow cytometry analysis by DA-Cell™ washer and plate for superior data and workflow | Namyong Kim, PhD; Melvin Lye | CAR T cells; Immune monitoring; Systems biology; T cell |
| P24 | Centrifuge-less red blood cell lysis and immunostaining of whole blood for flow cytometry using DA-Cell washer and plate | Melvin Lye; Namyong Kim, PhD | B cell; Biomarkers; CAR T cells; Immune monitoring; Immune tolerance; Immune toxicity |
| P25 | Consistent pharmacodynamics and immunological responses to the TLR9 agonist, SD-101, following intratumoral injection in multiple cancer types | Albert F. Candia, PhD; Cristiana Guiducci, PhD; Ezra Cohen, MD; Ronald Levy, MD; Mohammed Milhem, MBBS; Antoni Ribas, MD, PhD; Thomas Tuting, MD; Erick Gamelin, MD PhD; Robert S. Janssen, MD; Robert L. Coffman, Jr., PhD | Biomarkers; Checkpoint blockade; Clinical study; Dendritic cell; Gene expression; Immune monitoring; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P26 | High-dimensional flow cytometry of circulating immune cells predicts clinical responses to combination Immune Checkpoint Blockade (ICB) and Radiotherapy (RT) in Gastroesophageal Cancer (GEC) | Joseph Chao, MD; Wanqiu Hou; Yi-Jen Chen, MD, PhD; Helen Chen; Michael Tajon; Marwan Fakih, MD; Peter P. Lee, MD; | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Monocyte/Macrophage; Radiotherapy; Solid tumors; T cell |
| P27 | Tumor mutational burden assessment on FFPE samples using a targeted next-generation sequencing assay | Ruchi Chaudhary, PhD; Dinesh Cyanam, PhD; Vinay Mittal; Charles Scafe; Warren Tom, PhD; Janice Au-Young; Seth Sadis; Fiona Hyland | Bioinformatics; Biomarkers; Checkpoint blockade |
| P28 | Detection and validation of cancer immunotherapy biomarkers in blood and urine-based liquid biopsy | Simo Zhang; Shidong Jia; Amy Wang; Chen Xie | Bioinformatics; Biomarkers |
| P29 | Ensemble computational intelligence reveals novel molecular signatures of cancer biology and pan-cancer survival | Richard T. Williams; Thomas Chittenden; Nicholas A. Cilfone, x; Jeffrey R. Gulcher; | Bioinformatics; Biomarkers; Systems biology |
| P30 | Tracking the cancer immune response using neural network deep learning of serial inflammatory marker data for forecasting timing of therapy | Brendon J. Coventry, MD PhD; Mohsen Dorraki, MSc, BS; Anahita Fouladzadeh, BSc; Andrew Alison; Derek Abbott, PhD; Brendon J. Coventry, MD PhD; | Bioinformatics; Biomarkers; Immune monitoring; Inflammation; Solid tumors; Systems biology; Targeted therapy |
| P31 | Prevalence of high microsatellite instability in cancer patients in the real world | Razvan Cristescu, PhD; Kai-Li Liaw, PhD; Scott Pruitt, MD, PhD; Mark Ayers, PhD; Jianda Yuan, MD, PhD; Thao Vo, MD; Senaka Peter; Andrew Joe, MD PhD; Darcy Hille; Sun Young Rha; Torben Steiniche; Andrey Loboda, PhD | Biomarkers |
| P32 | Monitoring of M-MDSC vs. G-MDSC in clinical studies – which is more important? (monocytic versus granulocytic myeloid derived suppressor cells) | Henry Hepburne-Scott, PhD; Phoebe Bonner-Ferraby | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Granulocyte; Immune monitoring; Monocyte/Macrophage; Myeloid cells; MDSC |
| P33 | DNA damage detected by localized γH2AX is associated with elevated TILs and PD-L1 expression in human colorectal carcinomas. | Shruti Desai, PhD; Parker Sulkowski; Aravind N. Kalathil; Ranjini Sundaram; Ila J. Datar, PHD; Charles Fuchs, MD, MPH; Patricia LoRusso, DO; Ranjit S. Bindra; Kurt A. Schalper, MD, PhD | Biomarkers; Checkpoint blockade; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P34 | Clinical application of urinary cell free DNA as a marker for cancer | Jeffrey Ding; Debin Sun; | Biomarkers; Clinical study; Targeted therapy |
| P35 | Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928 | Daniel DiRenzo, PhD; Joanne BL. Tan, PhD; Devika Ashok, PhD; Amy Anderson, PhD; Jenna Jeffrey, PhD; Lisa Seitz, MSc; Manmohan R. Leleti, PhD; Steve W. Young, PhD; Jay P. Powers, PhD; Matthew J. Walters, PhD | Biomarkers; Gene expression; Tumor microenvironment |
| P36 | Defining the expression of Programmed Death-Ligand 2 in high grade glioma tumor microenvironment | Gifty A. Dominah; Victoria E. Sanchez, BS; John Lynes, MD; Nicholas Adamstein; Arnold Obungu, BS, BA; Xiang Wang, MS; Nancy Edwards, BA; Edjah K. Nduom, MD; | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor evasion; Tumor microenvironment |
| P37 | Multiplexed biomarker quantification to assay and characterize T-cell activation | Shilan Dong, MS; Jason G. Cahoon, BS; Rachit Ohri, PhD; Shilan Dong, MS; | Adoptive immunotherapy; Biomarkers; Costimulation; Cytokine; Immune monitoring; Immune suppression; Proteomics; T cell |
| P38 | Highly multiplex spatial immuno-profiling in FFPE tumor tissue with InSituPlex technology | Sean R. Downing, PhD; Abdul Mohammed, PhD; Abdul Mohammed, PhD; Gourab Chatterjee, PhD; Kevin Hwang, PhD; Julie Xia; Amanda J. Bares, PhD; Michael Murphy; Eloise Wheeler; Armen Changelian; Katir K. Patel, PhD; Bonnie Phillips, PhD; Mael Manesse, PhD | Antibody; Biomarkers; Immune contexture; Immune monitoring; Monocyte/Macrophage; Proteomics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P39 | PD-L1 expression on tumor versus antigen presenting cells investigated with multiplexed IHC using UltiMapper™ I/O assays | Amy Zhang, M.S.; Amy Zhang, M.S.; Alexis Wong, PhD; Max Rubinstein; Laura Sciarra, PhD; Chakib Boussahmain, Mr., B.S; Bonnie Phillips, PhD; Katir K. Patel, PhD; Sean R. Downing, PhD; Stephanie Hennek, PhD | Antibody; Antigen presenting cells; Biomarkers; Immune contexture; Immune monitoring; Immune suppression; Proteomics; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P40 | Intra-assay and inter-assay assessment of reproducibility and quantification of UltiMapperTM I/O PD-1 and PD-L1 immuno-oncology panels for tissue multiplexing | Bonnie Phillips, PhD; Bonnie Phillips, PhD; Katir K. Patel, PhD; Courtney Hebert; Jamie Buell; Sean R. Downing, PhD | Antibody; Biomarkers; Immune contexture; Immune monitoring; Monocyte/Macrophage; Proteomics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P41 | Characterization of circulating biomarkers in subjects with NSCLC using data independent acquisition mass spectrometry reveals host immune response mechanisms | Nicholas Dupuis, PhD; Jakob Vowinckel, PhD; Daniel Heinzmann; Claudia Escher | Biomarkers; Immune monitoring; Inflammation; Proteomics |
| P42 | Expanding insights into the colorectal cancer tumor proteome; unbiased protein profiling reveals multiple proteomic-based tumor subtypes | Jan Muntel; Roland Bruderer; Nicholas Dupuis, PhD; Lukas Reiter | Bioinformatics; Biomarkers; Gene expression; Proteomics; Solid tumors; Tumor microenvironment |
| P43 | The presence of exhausted CD8+ T cells identifies a subset of immunogenic ER+ breast cancer patient tumors | Colt Egelston, PhD; Christian Avalos; Diana L. Simons; Min Hui Lim; Peter P. Lee, MD | Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P44 | Discovery and screening of protein biomarkers with the FirePlex Technology Platform | Timothy P. Erps; Amy Perea, PhD; Russell Neuner, PhD; Bianca Heinrich, PhD; Wayne Austin; Conor Rafferty, PhD; Matt Camilleri; Long To; James Murray, PhD; Daniel Pregibon, PhD; Elnaz Atabakhsh, PhD | Bioinformatics; Biomarkers; Chemokine; Cytokine; Inflammation; Proteomics |
| P45 | Tumor infiltrating T cells: complete workflows allow faster and improved analysis | Cesar Evaristo, PhD; Ramona Siemer, BTA; Philipp Steinbrueck; Zhongjie Yu; David Agorku, BS; Olaf Hardt, PhD; Christian Dose, PhD; Anne Richter, PhD | Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P47 | Immune response in patients treated with autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC from the phase I, open label, dose escalation and cohort expansion study | Izak Faiena, MD; Nazy Zomorodian; Beata Berent-Maoz; Ankush Sachadeva; Adrian Bot, MD, PhD; Fairooz Kabinnavar; Jonathan Said; Gardenia Cheung-Lau; Jia Pang; Mignonette Macabali; Tinle Chodon; Xiaoyan Wang; Paula Cabrera; Paula Kaplan-Lezco; Sandy Liu; Begonya Comin-Anduix, PhD; Allan J. Pantuck, MD; Arie Belldegrun, MD, FACS; Karim Chamie, MD; Alexandra Drakaki, MD,PHD; Izak Faiena, MD; | Clinical trial; Dendritic cell |
| P48 | A high baseline neutrophil-to-lymphocyte ratio in patients receiving anti-PD-1 therapy for head and neck cancer associates with poor prognosis, tumor hypoxia, and tumor M2 macrophage predominance | Corey C. Foster, MD; Riyue Bao, PhD; Sara Kochanny, BA; Arun Khattri, PhD; Rajesh Acharya, MS; Allison Dekker, RN; Yi-Hung Carol Tan, PhD; Elaine Klema, BS; Ryan Brisson, BS; Vassiliki Saloura; Alexander T. Pearson, MD, PhD; Everett E. Vokes, MD; Rom Leidner, MD; Hisham Mehanna, PhD; Tanguy Seiwert, MD | Biomarkers; Checkpoint blockade; Gene expression; Immune monitoring; Monocyte/Macrophage; Solid tumors; Tumor microenvironment |
| P49 | Comprehensive immune and molecular analysis of a cohort of non-small cell lung cancer (NSCLC) patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1 | Joel Greshock; Ramaswamy Govindan, MD; Riley R. Curran; Rana Besada; Samantha J. Gates; Victoria Kohler; Meghan E. Bushway; Julian Scherer, PhD; Ying Sonia Ting; Yuting Huang, Master of Science; Yvonne Ware, Masters; April Lamb; Lisa D. Cleary; Melissa Moles; Joel Greshock; Richard B. Gaynor, MD; Matthew J. Goldstein, MD, PhD; Lakshmi Srinivasan | Antigen presenting cells; Biomarkers; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P50 | Characterization of T cell receptor repertoire from FFPE extracted RNA from glioblastoma patients by anchored multiplex PCR and next-generation sequencing | LAURA JOHNSON, PhD; Josh D. Haimes; Namitha M. Nair; Angelo Porciuncula, PhD; Kurt A. Schalper, MD, PhD; | Immune monitoring; T cell |
| P51 | Objective quantitative measurements of PD-L1 expression in tumor tissue by Phosphor Integrated Dots staining in patients with non-small cell lung cancer | Kazuyuki Hamada, MD, PhD.; Ryotaro Ohkuma, MD; Takehiro Takahashi, MD, PhD.; Takeshi Setogawa; Masaru Takahashi; Hisatake Okada; Hiroo Ishida; Yutaro Kubota, MD, PhD.; Hirotsugu Ariizumi, MD. PhD.; Etsuko Satoh, MD, PhD.; Yuya Hirasawa, MD; Yasutsuna Sasaki, MD, PhD.; Kiyoshi Yoshimura, MD, PhD.; Takuya Tsunoda, MD; Satoshi Wada, MD, PhD. | Biomarkers; Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs) |
| P52 | Emergence of an ICOShi CD4 T cell subset correlates with tumor reductions in subjects treated with the ICOS agonist antibody JTX-2011 | Amanda Hanson; Sean M. Lacey, MA Biostatistics; Courtney Hart; Ty McClure; Ellen Hooper, MD; Elizabeth G. Trehu, MD; Deborah Law, DPhil; Christopher Harvey, PhD | Biomarkers; Costimulation; Immune monitoring |
| P53 | X4P-001, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and tumor inflammatory status in the microenvironment of melanoma | Robert H. Andtbacka, MD, CM, FACS, FRCSC; Robert H. Pierce, Jr., MD; Jean S. Campbell, PhD; Melinda Yushak, MD, MPH; Mohammed Milhem, MBBS; Merrick Ross, MD; Katie Niland; Lu Gan, MD, PhD; Sudha Parasuraman, MD; Yan Wang, PhD | Antigen presenting cells; Biomarkers; Checkpoint blockade; Chemokine; Clinical study; Immune suppression; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P54 | Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444 | Andrew Hotson, PhD; Stephen Willingham, PhD; Lawrence Fong, MD; John D. Powderly, II, MD, CPI; Jason J. Luke, MD, FACP; Mario Sznol, MD; Saby George, MD, FACP; Toni K. Choueiri; Marios Giannakis, MD, PhD; Brian I. Rini, MD; Shivaani Kummar, MD; Erik Evensen; Ian McCaffery, PhD; Chunyan Gu; Long Kwei, PhD; Ginna Laport; Joseph J. Buggy; Richard A. Miller, MD; | Biomarkers; Clinical trial; Gene expression; Solid tumors; Tumor microenvironment |
| P55 | Within the secretome: Immunomodulatory role of extracellular vesicles in breast cancers. | Atousa khiabany, Mres; Fabian Flores-Borja, PhD; Ines García Carcedo; Felix Wong; Fabienne Beuron, PhD; Jose vicencio; Andrew Tutt; Tony Ng; SHEEBA IRSHAD, MD PhD | Immune tolerance; Inflammation; Tumor evasion; Tumor microenvironment |
| P56 | New Dextramer technology for T-cell epitope profiling, and single cell deep phenotyping using DNA barcodes, transcriptomic and genetic sequence analysis, on single cells | Kivin KJ. Jacobsen, PhD; Liselotte Brix, phd | Adoptive immunotherapy; Antigen presenting cells; Autoimmunity; Bioinformatics; Biomarkers; Carcinogenesis; Immune monitoring; Neoantigens; T cell; Tumor antigens |
| P57 | A rapid multi-color fluorescence imaging on frozen tissues | Dinesh Jaishankar, PhD; Cormac Cosgrove, PhD; Caroline Le Poole | Antibody; Immune monitoring |
| P58 | The use of low-coverage sequencing of cell-free DNA for monitoring response to immune checkpoint inhibitors throughout treatment | Taylor J. Jensen, Ph.D.; Aaron M. Goodman; Shumei Kato, MD; Mina Nikanjam; Christopher K. Ellison; Gregory A. Daniels, MD, PhD; Lisa Kim, M.S.; Kimberly Kelly, M.S.; Kerry Fitzgerald, Ph.D.; Erin McCarthy; Prachi Nakashe, M.S.; Amin R. Mazloom; Graham McLennan, M.S.; Daniel S. Grosu, MD, MBA; Mathias Ehrich; Razelle Kurzrock, MD | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Solid tumors; Systems biology |
| P59 | Assessment of consistency of multiplex fluorescent immunohistochemistry data across multiple users utilizing different quantitative analysis strategies | Shawn M. Jensen, PhD; Carmen Ballesteros Merino, PhD; Sebastian Marwitz; Nikhil Lonberg, HSDG; Bernard A. Fox, PhD | Biomarkers; Immune contexture; Immune monitoring; Immunoscore; Tumor microenvironment |
| P60 | Circulating tumor DNA assessment in plasma samples collected in Atezolizumab versus docetaxel in subjects with previously treated non-small-cell lung cancer (OAK) study | Yuqiu Jiang, PhD; Namrata S. Patil, Ph.D.; Johnny Wu; Wei Zou; Stephanie Yaung; Aarthi Balasubramanyam; Susan Flynn; Maureen Peterson; Eric Peters; Priti S. Hegde, PhD; Simonetta Mocci; Marcin Kowanetz, Ph.D.; John Palma | Bioinformatics; Biomarkers; Checkpoint blockade; Chemotherapy; Solid tumors |
| P61 | Development of an exosome / EV analysis pipeline for tumor and immune monitoring | Joshua A. Welsh, PhD; Kevin C. Conlon, MD; Milos Miljkovic, MD, MSc; Julia Kepley, BS; Jennifer Marte, BS MD; Jason Savage, PhD; Veronica Galli, PhD; Katherine McKinnon, MS; Katherine Calvo, MD, PhD; Hong Zhang; Cynthia Masison; Fatima Karzai, MD; Fatah Kashanchi; Deborah Citrin; Steve C. Jacobson; James L. Gulley, MD, PhD, FACP; Genoveffa Franchini, PhD; Thomas A. Waldmann, MD; Kevin Camphausen, MD, PhD; Jennifer C. Jones, MD, PhD; Jennifer C. Jones, MD, PhD; | Immune contexture; Immune monitoring; Leukemia/Lymphoma; Radiotherapy; Systems biology; Tumor microenvironment |
| P62 | A Pan-cancer view of the immune landscape in the tumor microenvironment via RNA and their potential for biomarkers in clinical trials | Wendell Jones; | B cell; Biomarkers; Gene expression; Monocyte/Macrophage; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P63 | Estimation of Microsatellite Instability (MSI) by next-generation sequencing using a novel MSI classification method | Sameh El-Difrawy; Annie Kraitcheva; Alice Zheng; Simon Crawley; Asha Kamat, PhD; | Bioinformatics; Biomarkers; Solid tumors |
| P64 | Evaluation of PD-L1 and IRF-1 expression on circulating tumor cells as a predictive biomarker of checkpoint inhibitor response | Laura C. Kennedy, MD PhD; Lance U'Ren, DVM, PhD; Yao Sun; Petros Grivas, MD, PhD; Laura Q. Chow, MD; Vijayakrishna Gadi, MD, PhD; | Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring |
| P65 | IDO/HLA-DR expression and tumor mutational burden are complementary predictive biomarkers of anti-PD-1 immunotherapy in squamous cell carcinoma of the head and neck | Arun Khattri, PhD; Ju Young Kim; Riyue Bao, PhD; Rajesh k. Acharya; Yi-Hung Carol Tan, PhD; Rom Leidner, MD; Hisham Mehanna, PhD; Nathan Roscoe; Christine A. Vaupel, PhD; Naveen Dakappagari; Tanguy Seiwert, MD; Sara Kochanny, BA; | Antigen presenting cells; Biomarkers; Checkpoint blockade; Immune monitoring; Neoantigens; Tumor infiltrating lymphocytes (TILs) |
| P66 | Evaluation of Immune – related Markers in circulating proteome and their association with atezolizumab efficacy in patients with 2L+ NSCLC | Marcin Kowanetz, Ph.D.; Ning Leng; Joanna Roder, PhD; Carlos Oliveira, PhD; Senait Asmellash, PhD; Krista Meyer, PhD; Heinrich Roder, DPhil; Marcus Ballinger, PhD; David Shames, Ph.D.; Marcin Kowanetz, Ph.D.; David Shames, Ph.D.; | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Immune suppression; Immunoscore; Inflammation; Proteomics; Solid tumors |
| P67 | Innovative combinatorial approach to characterize the immune landscape and analyze the tumor response after anti-PD-1 blockade in a 3D ex-vivo tumoroid system of non-small cell lung cancer | Melba Marie Page, Ph.D.; Melanie Mediavilla-Varela, PhD; Jenny Kreahling, PhD; Soner Altiok, MD, PhD | Antibody; Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P68 | Using high dimensional mass cytometry (CyTOF) and machine assisted analysis to detect biomarkers in the immunotherapy of cancer | Carsten Krieg, PhD; Silvia Guglietta; John M. Wrangle, MD; Luis E. Cardenas, B.S.; Mitchell Levesque; Reinhard Dummer, MD; Burkhard Becher;Mark P. Rubinstein, PhD; Mark Robinson; Carsten Krieg, PhD; | Biomarkers; Checkpoint blockade; Clinical trial; Cytokine; Immune monitoring; Inflammation; Monocyte/Macrophage; Myeloid cells; NK/NK T cell |
| P69 | Simultaneous quantification of activated immune cells and PD-L1 expressing circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy | Rachel Krupa, BS; Robin Richardson; Priscilla Ontiveros; Joseph Schonhoft; Yipeng Wang, PhD, MD; Jiyun Byun, MS; David Lu; Aaron Oh; Sean Nisperos; Mark Landers, MS; Ryan Dittamore, MS | Biomarkers; Checkpoint blockade; Immune monitoring; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P70 | CD4+FOXP3+ regulatory T cells in the periphery of HNSCC patients demonstrate high phenotypic diversity depending on Treg subtype | Cornelius Kürten, MD; Shanhong Lu; Tullia C. Bruno, PhD; Robert L. Ferris, MD, PhD | Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Systems biology; Tumor evasion; Tumor microenvironment |
| P71 | Characterization of tumor mutational burden (TMB) and homologous recombination repair (HRR) mutations to assess correlation with immune checkpoint inhibitors (ICIs) response in renal cell carcinoma | Matthew K. Labriola, MD; Jason Zhu, MD; Rajan Gupta; Shannon J. McCall, MD; Jennifer JJ. Jackson, PhD; James White, PhD; Elizabeth Weingartner; Eric Kong; Peter Simone, Ph.D.; Eniko Papp, Ph.D.; Kelly Gerding, Ph.D.; Eun-Hae Kim, Ph.D.; John K. Simmons, PhD; Daniel J. George, MD; Tian Zhang, MD; Tian Zhang, MD; | Biomarkers; Checkpoint blockade; Solid tumors |
| P72 | Biomarker and preliminary pharmacodynamic evaluations of the PD-1 inhibitor ABBV-181 from an ongoing phase 1 clinical trial in patients with advanced solid tumors | Stacie L. Lambert; Gregory Vosganian, MD; Fiona Harding, PhD; James Sheridan; Stefan Englert, Dr.; Sara Siggelkow; Apurvasena Parikh, PhD; Betty Wang; Kinjal Hew; Jaishree Bankoti; Marcia Stickler; Eileen Lee; Merriam Mcclellan; Daniel Afar, PhD; Anita Reddy, PhD; Stacie L. Lambert; | Biomarkers; Checkpoint blockade; Clinical trial; Solid tumors; T cell |
| P73 | Analysis of survival and mRNA expressivity in the tumor microenvironment of adenocarcinoma via K-means clustering algorithm | Seongwon Lee, PhD; Andrew Baird, MD; Jillian Dolan, BS; Stuart Baird; Fateeha Furqan, MD; Shinyoung Park, MS; Sunyoung S. Lee, MD, PhD; | Gene expression; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P74 | Validation the immune contexture as prognostic biomarkers in high-grade serous ovarian cancer | Shin Wha Lee, MD; Ju-hyun Kim; Soo-Jung Kim; Yong-Man Kim | Immune contexture; Immunoscore |
| P75 | Development of a next-generation sequencing-based microsatellite instability assay (MSI-NGS) for solid tumor testing | Sean T. Glenn, PhD; Sarabjot Pabla, MSc, PhD, BS; Jonathan Andreas, MS; Blake Burgher, BS, RN; Jacob Hagen; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Vincent Giamo, BS, MS; Felicia L. Lenzo; Maochun Qin, MD, MS; Yirong Wang, M.S.; Mark Gardner; Carl D. Morrison, MD, DVM | Biomarkers; Solid tumors |
| P76 | Analysis of the complex immune-cell milieu of tumors from patients treated with immunotherapy to better understand clinical response | Shumei Kato, MD; Ryosuke Okamura; Mina Nikanjam; Ramez N. Eskander, MD; Paul Fanta, MD; Suzanna Lee; Sean T. Glenn, PhD; Devin Dressman, PhD; Sarabjot Pabla, MSc, PhD, BS; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Felicia L. Lenzo; Mark Gardner; Carl D. Morrison, MD, DVM; Razelle Kurzrock, MD | Biomarkers; Gene expression; Solid tumors; T cell; Tumor microenvironment |
| P77 | Identifying major immune-related subsets of GI tumors for clinical purposes | Amy P. Early, MD; Sarabjot Pabla, MSc, PhD, BS; Jeffrey Conroy, BS; Mary Nesline, MS; Sean T. Glenn, PhD; Felicia L. Lenzo; Antonios Papanicolau-Sengos, MD; Blake Burgher, BS, RN; Vincent Giamo, BS, MS; Jonathan Andreas, MS; Yirong Wang, M.S.; Carl D. Morrison, MD, DVM | Biomarkers; Immune monitoring; Solid tumors; Tumor microenvironment |
| P78 | More sensitive identification of T-cell receptor beta rearrangements with an augmented transcriptome method | Sean M. Boyle, PhD; Eric Levy, PhD; Gabor Bartha; Pamela Milani; Robin Li; Shujun Luo; Rena McClory; John S. West, MBA; Richard Chen | Bioinformatics; Biomarkers; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P79 | Change in neutrophil to lymphocyte ratio during treatment with immune checkpoint inhibitors predicts survival in patients with advanced cancer | Dan Spakowicz, PhD, MS; Jarred Burkart; Sandip Patel; Marium Husain, MD, MPH; Kai He, MD, PhD; Carolyn Presley; Erin Bertino; Peter Shields; David P. Carbone, MD, PhD; Claire Verschraegen, MD; Greg Otterson; Kari Kendra; Mingjia Li, MD; Dwight Owen | Biomarkers; Checkpoint blockade; Immune monitoring; Inflammation |
| P80 | Day-to-day profiling of T cell activation by measuring cellular markers and secreted cytokines in a rapid multiplexed cell/bead mixture assay | Zhaoping Liu, Ph.D.; | Adoptive immunotherapy; Biomarkers; CAR T cells; Checkpoint blockade; Cytokine; Immune monitoring; Immune suppression; Immune tolerance; T cell; Tumor evasion |
| P81 | Germline encoded TRBV polymorphism predicts adverse events during checkpoint blockade immunotherapy | Timothy Looney, PhD; Geoffrey M. Lowman, PhD; Asha Kamat, PhD; Fiona Hyland | Autoimmunity; Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Immune monitoring; Immune toxicity; T cell |
| P82 | Peripheral blood TCRB repertoire convergence and clonal expansion predict response to anti-CTLA-4 monotherapy for cancer | Timothy Looney, PhD; Li Zhang, MD PhD; David Y. Oh, MD, PhD; Denise S. Topacio-Hall, BS, MA; Lawrence Fong, MD | Bioinformatics; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; T cell; T cell lineages; Tumor antigens |
| P83 | T cell receptor beta immune repertoire sequencing in several FFPE tissue types – Interrogation of the tumor microenvironment in archived tissue samples | Denise S. Topacio-Hall, BS, MA; Lauren Miller, BS; Elizabeth Linch, BS; Alice Zheng, PhD; Geoffrey M. Lowman, PhD; Timothy Looney, PhD; Mark Andersen, PhD | Biomarkers; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P84 | Quantitative evaluation of tumor-infiltrating lymphocyte subsets and PD-L1 expression in lung cancer brain metastases | Benjamin Y. Lu, MD; Richa Gupta; Hailey Wyatt; Matthew Ribeiro; Tyler Stewart; Veronica Chiang, MD; Joseph Contessa; Adebowale Adeniran; Harriet Kluger, MD; Lucia Jilaveanu, MD; Kurt A. Schalper, MD, PhD; Sarah B. Goldberg, MD, MPH | Immune monitoring; Immune suppression; Inflammation; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P85 | Correlation of clinical response and pathologic treatment effect after 4 weeks of preoperative PD-1 blockade in primary head and neck squamous cell carcinoma (HNSCC) | Adam Luginbuhl, MD; Jennifer Johnson, MD; Madalina Tuluc, MD; Stacey Mardekian, MD; Chandala Chitguppi, MD; Larry Harshyne, PhD; Ralph G. Zinner, MD; Joseph Curry, MD; David Cognetti, MD; Ulrich Rodeck, MD PhD; Athanassios Argiris, MD PhD | Checkpoint blockade; Clinical trial; Immune monitoring; Immunoscore; Solid tumors; Surgery; Tumor microenvironment |
| P86 | T-cell receptor (TCR) repertoire features associated with disease-free survival following infusion with marrow-infiltrating lymphocytes (MILs) | Eric R. Lutz, PhD; Alex Hopkins, PhD; LAKSHMI RUDRARAJU, MS; Elizabeth DeOlivera; Ido Weiss, PhD; Rachel Gittelman, PhD; Erik Yusko, PhD; Kathryn G. Boland, DVM, PhD; Ivan M. Borrello, MD; Kimberly A. Noonan, Ph.D.; | Adoptive immunotherapy; Biomarkers; Immune monitoring |
| P87 | Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial | Susan K. Lyman; Judi Gordon; Amy DuPage; Preeti Pramanik; Bruce Howng; Michael B. Winter; Irina K. Popova; Olga Vasiljeva; James Jones; Kenneth R. Wong, MA; Victoria Singson; Jennifer H. Richardson, PhD; Beiyao Zheng, PhD; Mark Stroh, PhD; Lori Carman, RN; Vanessa Huels; Karen Autio, MS, MD; Valentina Boni; Daniel C. Cho, MD; Javier Garcia-Corbacho; Iván Victoria Ruiz; Omid Hamid, MD; Nataliya Uboha; Elisabeth de Vries; Anthony El-Khoueiry, MD; Alexander I. Spira, MD, PhD, FACP; Rachel E. Sanborn, MD; Fiona Thistlethwaite, MD, PhD; Hendrik-Tobias Arkenau; Johanna Bendell; Patrick A. Ott, MD, PhD; Naiyer A. Rizvi, MD; Matthias Will, MD; W. Michael Kavanaugh, MD; Aung Naing, MD, FACP; Luc R. R. Desnoyers, Ph. D. | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune monitoring; Leukemia/Lymphoma; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P88 | Quantitative assessment and standardization of the programmed death 1 ligand 1 (PD-L1) immunohistochemistry companion diagnostic assays | Sandra Martinez-Morilla, PhD; John McGuire; Patricia Gaule, PhD; Lauren Moore; Balazs Acs; Delphine Cougot; David L. Rimm, MD, PhD; | Antibody; Biomarkers; Checkpoint blockade; Targeted therapy |
| P90 | Using artificial intelligence to predict response to immunotherapy | Joseph S. Krueger, BS PhD; Karen Ryall, PhD, BS; Navi Mehra; Jenifer Caldara, BS; Will Paces, BS; Kelsey Weigel, PhD | Biomarkers; Checkpoint blockade; Clinical trial; Immune contexture; Immune suppression; Immune tolerance; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P91 | It’s pan-o’clock: Tumor and circulating lymphocytic pan-pathology targets of the failed immune response | Anne Monette, PhD; Antigoni Morou, PhD; Nadia Al-banna; Louise Rousseau, RT; Jean-Baptiste Lattouf, MD, FRCSC; Sara Rahmati; Tomas Tokar; Daniel Kaufmann, MD; Jean-pierre Routy; Igor Jurisica, PhD; Rejean Lapointe, PhD | B cell; Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P92 | Predictive plasma proteomic biomarkers of immunotherapy toxicity in patients (pts) with metastatic melanoma (MM) | Meghan J. Mooradian, MD; Xuesong Gu; Donald Lawrence, MD; Justine V. Cohen, DO; Tatyana Sharova; Genevieve M. Boland, MD, PhD; Towia A. Libermann; Ryan J. Sullivan, MD; | Biomarkers; Immune monitoring; Immune toxicity; Proteomics; Solid tumors |
| P93 | Pre-analytical variables affect myeloid-derived suppressor cell quantitation by flow cytometry | Chihiro Morishima, MD; Amy E. Wright; Angela M. Riggins; Chihiro Morishima, MD; Minjun Apodaca | Biomarkers; Immune monitoring; Myeloid cells; MDSC |
| P94 | Measurement of adenosine and other immunomodulators in the tumor microenvironment by in vivo microdialysis | Nadege Morisot, PhD; Julien Roeser, PhD; Holden Janssens, PhD; Arash Rassoulpour, PhD | Biomarkers; Immune contexture; Immune monitoring; Solid tumors; Tumor microenvironment |
| P95 | Modulation of adenosine levels in the tumor microenvironment following treatment with anti-PD1 antibodies and oxaliplatin: an in vivo microdialysis study | Arash Rassoulpour, PhD; Nadege Morisot, PhD; Julien Roeser, PhD; Holden Janssens, PhD | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Solid tumors; Targeted therapy; Tumor microenvironment |
| P96 | Assessment of RNA turbulence and PD-L1 expression on tumor-infiltrating lymphocytes in breast cancer | Apoorva L. Mylavarapu, BS; Scott Morris; Maulik Patel, PharmD, PhD; Sandip P. Patel, MD | Biomarkers; Gene expression; Tumor infiltrating lymphocytes (TILs) |
| P97 | Different functionality of CD8 PD-1-positive CD28-negative T cells in the periphery and in the tumor of lung cancer patients | Belinda Palermo; Ornella Franzese; Mariangela Panetta; Giulia Campo; Fabiana Cecere; Virginia Ferraresi; Gabriele Alessandrini; Francesco Facciolo; Gennaro Ciliberto, MD; Paola Nistico', MD | Checkpoint blockade; Coinhibition; Costimulation; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P98 | High gene expression of estrogen and progesterone receptor is associated with increased T cell infiltration in patients with NSCLC | Michael S. Oh, MD; Jonathan Anker, MD; Young Kwang Chae, MD; | Gene expression; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P99 | RRx-001 is a Phase 3-Ready small molecule dual inhibitor of CD47 and SIRPalpha | Pedro Cabrales, PhD; Bryan Oronsky, MD PhD; Tony Reid, MD PhD; Corey A. Carter, MD; | Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; Immune suppression; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P100 | Exploring dissociated human tissues as an alternative to fresh tissue for multiple downstream applications | Shawn Fahl, Ph.D.; | B cell; Biomarkers; Myeloid cells; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P101 | Evaluation of ctDNA mutations detected in plasma as potential correlate of immunotherapy efficacy in NSCLC patients | Namrata S. Patil, Ph.D.; Yuqiu Jiang, PhD; Wei Zou; Johnny Wu; Stephanie Yaung; Susan Flynn; Maureen Peterson; Eric Peters; Priti S. Hegde, PhD; Marcin Kowanetz, Ph.D.; John Palma; Namrata S. Patil, Ph.D.; David Shames, Ph.D.; Yuqiu Jiang, PhD; Namrata S. Patil, Ph.D.; | Biomarkers; Clinical trial; Neoantigens |
| P102 | Localized measurement and clinical significance of OX40 and OX40L expression in human non-small cell lung cancer (NSCLC) | Angelo Porciuncula, PhD; Micaela Morgado; Sima Zacharek, PhD; Maria Toki, MD, MSc; Kostas Syrigos; Vamsidhar Velcheti, MD FACP; Joshua Frederick, PhD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD | Costimulation; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P103 | Bulk and single-cell TCR and transcriptome profiling reveals significant phenotypic, spatial and temporal heterogeneity in the TIL repertoire of pancreatic cancer and melanoma patients | Chin Leng Tan; Ignacio Heras-Murillo, MSc.; Katharina Lindner; Aaron Rodriguez Ehrenfried; Lena Appel; Anna-Katharina Koenig; Markus Buechler; Ugur Sahin, MD; Jessica Hassel; Oliver Strobel; Michael Flossdorf; Rienk Offringa, PhD; Isabel Poschke, PhD | Adoptive immunotherapy; Immune contexture; Immune monitoring; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P104 | Radiomic features that can predict response to PD-1 inhibitors in late-stage Non-Small Cell Lung Cancer are also associated with tissue-derived measures of immune response | Prateek Prasanna, PhD; Mohammadhadi Khorrami, PhD; Pradnya Patil; Kaustav Bera, MBBS; Vamsidhar Velcheti, MD FACP; Anant Madabhushi, PhD; | Biomarkers; Immune monitoring; Tumor infiltrating lymphocytes (TILs) |
| P105 | Response to immunotherapy in hepatocellular carcinoma, a single-institutional analysis | Petra Prins; Bhavana P. Singh, MD; AIwu He | Biomarkers; Chemotherapy; Solid tumors; Targeted therapy |
| P106 | Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment (TME) across tumor types | Jason Ptacek, PhD; Rachel Finck; Murat Aksoy; Jay Tarolli; Jessica Finn; | Biomarkers; Immune monitoring; Immune suppression; Monocyte/Macrophage; Proteomics; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P107 | A comparative study of the PD-L1 IHC 22C3 and 28-8 assays in melanoma samples | Gabriel S. Krigsfeld, Ph.D.; Kim Zerba; James Novotny Jr; Shuntae Williams; Michael Matthews, M.S.; Hytham Al-Masri, PhD; David Gold; James White | Antibody; Biomarkers; Checkpoint blockade; Solid tumors |
| P108 | HLA class I subtypes are associated with immune-related adverse events in patients with melanoma treated with ipilimumab | Anton Safanov; John Pluta; Lu Qian; Ravi Amaravadi; Allison Applegate; Elizabeth Buchbinder, MD; Justine V. Cohen, DO; Claire Friedman, MD; Ruth Halaban, PhD; F. Stephen Hodi, Jr., MD; Christine E. Horak, PhD; Douglas B. Johnson, MD, MSCI; John M. Kirkwood, MD; Tara C. Mitchell; William A. Robinson, MD, PhD; Lynn M. Schuchter, MD; Jeffrey A. Sosman, MD; Mario Sznol, MD; Megan Wind-Rotolo, PhD; Jedd D. Wolchok, MD, PhD; Mingyao Li; Peter Kanetsky; Katherine L. Nathanson | Antigen presenting cells; Autoimmunity; Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Immune toxicity; Tumor microenvironment |
| P109 | Clinical efficacy of immune checkpoint inhibitors in patients with small cell lung cancer is associated with high tumor mutational burden and development of immune-related adverse events | Biagio Ricciuti, MD; Suzanne Dahlberg; Sasha Kravets; Safiya Subegdjo; Renato Umeton; Adem Albayrak, M.S.; Lynette M. Sholl; Mark M. Awad | Biomarkers; Checkpoint blockade; Immune toxicity |
| P110 | Modular repertoire analysis of blood transcriptomic immune response in metastatic renal cell carcinoma patients treated with Pazopanib | Darawan Rinchai, PhD; Elena Verzoni; Agata Cova; Paola Squarcina; Loris D. Cecco; Paolo Grassi; Raffaele Ratta; Veronica Huber; Matteo Dugo; Monica Rodolfo; Jessica Roelands, Master; Damien Chaussabel; Giuseppe Procopio; Davide Bedognetti, MD, PhD; Licia Rivoltini, MD; | Bioinformatics; Clinical study; Gene expression; Immune monitoring; Immune suppression; Systems biology |
| P111 | Streamlined human immune monitoring with mass cytometry: 29 markers in a single tube with automated data analysis | Christina Loh, PhD; Thiru Selvanantham, PhD; Leslie Fung; Michelle M. Poulin; C. Bruce Bagwell; Margaret Inokuma; Clare Rogers, MS; Greg Stelzer, PhD; Steven Lott, PhD | B cell; Bioinformatics; Biomarkers; CAR T cells; Immune monitoring; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells; Proteomics; T cell |
| P112 | Proteomic profiling of biomarkers for response to checkpoint immunotherapy in melanoma patients | Marijana Rucevic, PhD; | Biomarkers; Checkpoint blockade; Immune monitoring; Proteomics |
| P113 | Digital spatial profiling of bone-marrow infiltrating immune cells in acute myeloid leukemia. | Sergio Rutella, MD, PhD, FRCPath; Jayakumar Vadakekolathu, PhD; Sarah E. Church; Heidi Altmann; Elena Viboch, MS; Jorn Meinel, MD; Yan Liang, MD PhD; Joseph M. Beechem, PhD; Alessandra Cesano, MD, PhD; Sarah Warren, PhD; Gerhard Enhinger, MD; Marc Schmitz, MD; Martin Bornhauser, MD; Sergio Rutella, MD, PhD, FRCPath; | Gene expression; Immune contexture; Immune suppression; Immune tolerance; Leukemia/Lymphoma; Monocyte/Macrophage; Tumor evasion; Tumor microenvironment |
| P114 | ImmunoINTEL, a flow cytometry based platform that identifies and quantifies the most critical cell subsets and related functional potential in dissociated solid tumors | Konstantin Salojin, PhD; Christine Hauther; Dai Liu; Santosh Putta; Norman B. Purvis, Jr., PhD; Matt Westfall, PhD | Biomarkers; Immune monitoring; Immunoscore; Monocyte/Macrophage; MDSC; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P115 | Predictive and pharmacodynamic biomarkers associated with treatment with the oral selective AXL Inhibitor bemcentinib in combination with pembrolizumab in patients with advanced NSCLC and Melanoma | Robert Holt, PhD; David Micklem, PhD; Anthony Brown; Cornelia Schuster; Oddbjørn Straume; James Lorens, PhD | Biomarkers; Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Coinhibition; Cytokine; Targeted therapy |
| P116 | Quantitative measurement of CD8, CD68 and PD-L1 expression in a novel multiplex assay and associations of overall survival in non-small cell lung cancer (NSCLC) patients treated with anti-PD-1 Therapy | Fahad S. Shabbir, MD; Jon Zugazagoitia, MD; Yuting Liu, PhD candidate; Katir K. Patel, PhD; Brian S. Henick, MD; Scott N. Gettinger, MD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD; David L. Rimm, MD, PhD | Antibody; Biomarkers; Checkpoint blockade; Immune monitoring; Monocyte/Macrophage; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P117 | Host immune response in undifferentiated pleomorphic sarcoma – 10-year retrospective analysis | Joseph Sheridan; Andrew Horvai; Ross Okimoto; Rosanna Wustrack; | Immune monitoring; Solid tumors; Surgery; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P118 | Immunosuppression involving MDSC and IL-17 is associated with decreased levels of serum rapid turnover protein and shorter survival in patients with gastrointestinal cancer | Masahiko Shibata, MD; Kenji Gonda, MD, PhD; Takahiro Nakajima; Tatsuo Shimura; Koji Kono; Seiichi Takenoshita; | Biomarkers; Cytokine; Immune suppression; Immune tolerance; Inflammation; Myeloid cells; MDSC |
| P119 | Fab-selective proteolysis coupled with liquid chromatography-mass spectrometry for monitoring therapeutic antibodies in circulation | TAKASHI SHIMADA, PhD; Noriko Iwamoto, PhD | Antibody; Biomarkers; Immune monitoring |
| P120 | Validated next generation sequencing assay for the characterization of the T-cell repertoire from RNA | Jennifer K. Sims; Martin Buchkovich, PhD; Jason Powers; Victor J. Weigman, Jr.; John Pufky; Jennifer Mason, PhD; Patrick Hurban, PhD | Biomarkers; Immune monitoring; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P121 | Interaction of immune checkpoints in tumor-stromal microenvironment of primary and chemoreduced retinoblastoma | Lata Singh, Ph.D.; Mithalesh K. Singh; Seema Kashyap; Seema Sen, MD; Moshahid A. Rizvi, PhD; | Chemotherapy; Pediatric tumors; Tumor microenvironment; Tumor stroma |
| P122 | Validated next generation sequencing RNA-based assay of the IGHV mutation status and repertoire diversity | Jeran Stratford; Jennifer K. Sims; Patrick Hurban, PhD; Victor J. Weigman, Jr.; | Antibody; B cell; Bioinformatics; Biomarkers; Immune monitoring |
| P123 | Peripheral blood lymphocyte responses in patients with renal cell carcinoma treated with high-dose interleukin-2 | Rupal Bhatt, MD, PhD; Lei Sun, Ph.D; William J. Slichenmyer, MD; Sean Rossi; Juan C. Alvarez, PhD; Wenxin Xu, MD; Heather C. Losey, PhD | Biomarkers; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P124 | Quantitative multichannel immunofluorescence imaging to assess the immune composition of the T cell-inflamed tumor microenvironment in bladder cancer | Randy F. Sweis, MD; Ken Hatogai; Danny Kim; Yuanyuan Zha, PhD; Alexander T. Pearson, MD, PhD; Gary D. Steinberg, MD; Thomas F. Gajewski, MD, PhD; | Antigen presenting cells; Biomarkers; Checkpoint blockade; Dendritic cell; Immune contexture; Immune monitoring; Inflammation; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P125 | DNA methylation biomarkers for noninvassive detection of hepatocellular carcinoma | David J. Taggart, PhD; Dhruvajyoti Roy, PhD; Gen Li; Dan Liu; Lianghong Zheng; Kang Zhang; | Biomarkers; Clinical study; Solid tumors |
| P126 | Peripheral immune monitoring identifies biomarkers of response and toxicity after neoadjuvant combination immunotherapy with ipilimumab (ipi) and high dose IFNα2b (HDI) in patients with melanoma | Ahmad A. Tarhini, MD, PhD; Ghanashyam Sarikonda; Arjun Khunger, MD; Jack El-Sawada, MD; Christian Laing; Christine A. Vaupel, PhD; Naveen Dakappagari | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Immune monitoring; MDSC; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P127 | Characterization of changes in tumor immune microenvironment after treatment with neoadjuvant combination immunotherapy with ipilimumab (ipi) and high dose IFNα2b (HDI) in patients with melanoma | Arjun Khunger, MD; Jennifer Bordeaux, PhD; Ju Young Kim; Christine A. Vaupel, PhD; Naveen Dakappagari; Ahmad A. Tarhini, MD, PhD | Biomarkers; Checkpoint blockade; Immune monitoring; MDSC; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P128 | Multiplexed immunofluorescent assay development for study of the PD-1/PD-L1 checkpoint in the tumor immune microenvironment (TIME) | Sneha Berry, MS; Nicolas A. Giraldo, MD PhD; Peter Nguyen, MS; Benjamin Green, BS; Haiying Xu; Aleksandra Ogurtsova; Abha Soni, DO; Farah Succaria, MD; Daphne Wang, MS; Charles Roberts; Julie E. Stein, MD; Elizabeth L. Engle, MSc; Drew M. Pardoll, MD, PhD; Robert A. Anders, MD, PhD; Tricia Cottrell, MD, PhD; Janis M. Taube, MD, MSC | Biomarkers; Checkpoint blockade; Solid tumors; Tumor microenvironment |
| P129 | Simultaneous single cell analysis of multiple analytes resolves T cell populations at high resolution | Sarah Taylor, PhD; Katherine A. Pfeiffer; Michael JT. Stubbington, PhD; Josephine Y. Lee; Jerald Sapida; Liselotte Brix, phd; Kivin KJ. Jacobsen, PhD; Bertrand Yeung; Xinfang Zhao; Tarjei Mikkelsen; Deanna M. Church, PhD | Antigen presenting cells; Gene expression; Immune monitoring; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P130 | A measurable immune response in the tumors and lymph nodes of patients with lymph node positive and lymph node negative breast cancer. | Archana Thakur, PhD; Dana L. Schalk; Tayson Lin; Griffin R. Calme, B.S.; Johnson Ung; Lawrence G. Lum, MD, DSc; Lydia Choi | Biomarkers; Immunoscore; T cell; Tumor infiltrating lymphocytes (TILs) |
| P131 | High-plex predictive marker discovery for melanoma immunotherapy treated patients using NanoString® Digital Spatial Profiling | Maria Toki, MD, MSc; Pok Fai Wong, MD, MPhil; James W. Smithy, MD, MHS; Harriet Kluger, MD; Chris Merritt, PhD; Giang Ong, MS; Sarah Warren, PhD; Joseph M. Beechem, PhD; David L. Rimm, MD, PhD | Biomarkers; Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P132 | RNA sequencing of rare antigen-specific T cells and tissue micro-regions using the RareCyte platform | Lance U'Ren, DVM, PhD; Rebecca Podyminogin; Nolan Ericson; Eric Kaldjian, MD; Tad George, PhD | Biomarkers; Immune contexture; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P133 | Spatially resolved and multiplexed immunoprofiling of NSCLC using imaging mass cytometry reveals distinct functional profile of CD4 and CD8 TILs associated with response to immune checkpoint blockers | Franz Villarroel-Espindola, Ph.D.; Miguel F. Sanmamed, MD, PhD; Jonathan Patsenker; Ya-Wei Lin; Brian S. Henick, MD; Jovian Yu; Mark Verburg; Tayf Badri; Jon Zugazagoitia, MD; Daniel E. Carvajal-Hausdorf, MD; Ruth Montgomery, Ph.D.; Roy S. Herbst, MD, PhD; Lieping Chen, MD, PhD; David L. Rimm, MD, PhD; Tal Shnitzer, Ph.D.; Ronen Talmon, Ph.D.; Yuval Kluger, Ph.D.; Kurt A. Schalper, MD, PhD; | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P134 | Prognostic and predictive value of baseline biomarkers in advanced non-small cell lung cancer (NSCLC) | Huifen Wang, PhD; Robert McEwen; Ketan Patel, PhD; Binbing Yu; J Carl Barrett; Kris Sachsenmeier, PhD | Adoptive immunotherapy; Biomarkers |
| P135 | Integrative genomic and proteomic analysis identifies cancer subtypes and signaling networks associated with aberrant tumor expression of VISTA | Duncan Whitney, PhD; Anna W. Ma, MS; Ramachandra Mu. Katabathula, Ph.D.; Timothy Wyant; Jefferson Parker; Salendra Singh, MS; David Tuck; Vinay Varadan, PhD; | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Tumor stroma |
| P136 | Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of the VEGF receptor inhibitor axitinib plus pembrolizumab | Breelyn A. Wilky, MD; SuFey Ong; Sarah Warren, PhD; Alessandra Cesano, MD, PhD; Despina Kolonias; Eric Wieder, PhD; Deukwoo Kwon, PhD; Andrew Rosenberg, MD; Jonathan C. Trent, MD, PhD; Krishna Komanduri, MD | Angiogenesis; Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Solid tumors |
| P137 | A systematic literature review (SLR) of tumor mutational burden (TMB) and efficacy with immunotherapy (IO) in lung cancer | Connor Willis, PharmD; Michelle Fiander; Dao Tran, PharmD; Beata Korytowsky; John-michael Thomas, PharmD; Signe Fransen; Florencio Calderon; Teresa Zyczynski; Lisa Siegartel; Diana Brixner; David Stenehjem; Connor Willis, PharmD; | Biomarkers; Checkpoint blockade; Solid tumors |
| P138 | Quantitative assessment of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma | Pok Fai Wong, MD, MPhil; Wei Wei, MD, PhD; Swati Gupta, PhD; James W. Smithy, MD, MHS; Harriet Kluger, MD; David L. Rimm, MD, PhD | Biomarkers; Checkpoint blockade; Clinical study; Solid tumors; Tumor microenvironment; Tumor stroma |
| P139 | Pharmacodynamic effects of CA170, a first-in-class small molecule oral immune checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor of T-cell activation (VISTA) and PD-L1 | Timothy L. Wyant, PhD; Hongwei Wang, MD, PhD; David Tuck; Yung-Jue Bang, MD PhD; Anna W. Ma, MS; Jeffrey A. Sosman, MD; Adil Daud, MBBS MD; John D. Powderly, II, MD, CPI; Javier Garcia-Corbacho; Manish R. Patel, MD; James J. Lee, MD, PhD; Kyu-Pyo Kim; Joshua Brody, MD; Sun Young Rha; Erika P. Hamilton, MD; Marta Gil Martin; Santiago Ponce Aix, MD; Radhakrishnan Ramchandren, MD; Myung-Ju Ahn; James Spicer, MD, PhD; Simon Pacey; Gerald S. Falchook, MD; Funda Meric-Bernstam, MD | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs) |
| P140 | Deep profiling of Asian NSCLC to identify the tumor antigen-specific T cells and the predictive potential of the patients treated with PD-1/PD-L1 blockade | Joe P. Yeong, MBBS, PhD; Lisda Suteja; Yannick Simoni; Kah Weng Lau; Sherlly Lim; Jie Hua, Josh Loh; Angela Takano; Eng Huat Tan, MD; Kiat Hon, Tony Lim; S. W., Daniel Tan; Evan W. Newell, PhD; | Adoptive immunotherapy; Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P141 | Circulating tumor DNA ( ctDNA) a novel biomarker for immunotherapy response in advanced lung cancer | Ebenezer O. Appah, MD; Katherine B. Neblett; Clive D. Morris; Greg Jones; Vincent Plagnol; Paul R. Walker, MD; Meera Yogarajah, MD | Checkpoint blockade; Immune monitoring |
| P142 | The immunogenomic impact of indoximod on the tumor microenvironment of melanoma patients | Jiayi Yu, PhD; Gabriela R. Rossi, PhD; Ravindra Kohle, MD, PhD; David H. Munn, MD; Yousef Zakharia, MD; Nicholas Vahanian, MD; Eugene P. Kennedy, MD, FACS; Charles Link, Jr., MD | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Solid tumors; Tumor microenvironment |
| P143 | Rational combination of GITR agonism with PD-1 blockade in cancer patients | Roberta Zappasodi, PhD; Cynthia Sirard, MD; Yanyun Li, PhD MD; Sadna Budhu, PhD; Moshen Abu-Akeel; Cailian Liu, MD; Xia Yang; Hong Zhong, BS; Walter Newman, PhD; Jingjing Qi; Phillip Wong, PhD; David Schaer; Henry Koon, MD; Vamsidhar Velcheti, MD FACP; Michael Postow, MD; Margaret K. Callahan, MD, PhD; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; | Biomarkers; Checkpoint blockade; Costimulation; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P144 | A fully-automated multiplex fluorescence IHC assay with whole slide multispectral imaging on mouse tissue: phenoptics™ quantitative pathology solutions translational workflow | Yi Zheng, PhD; Carla Coltharp, PhD; Ryan Dilworth, PhD; Rachel Schaefer; Linying Liu; Victoria Duckworth; William Kennedy; Darryn Unfricht, PhD; Peter Miller, MS; Milind Rajopadhye, PhD; | Biomarkers; Regulatory T cell (Treg cell); Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma |
| P145 | Computational assessment of IDO1 feedback modulation | JIAN ZHU, PhD; Rebecca L. Zhu | Bioinformatics; Biomarkers; Immune suppression; MDSC; NK/NK T cell; Regulatory T cell (Treg cell); Systems biology; Tumor infiltrating lymphocytes (TILs) |
| P146 | Cell proliferation improves prediction for immune checkpoint inhibitors (ICIs) response in PD-L1 positive TMB high non-small cell lung cancer (NSCLC) | Jason Zhu, MD; Matthew K. Labriola, MD; Daniele Marin, MD; Shannon J. McCall, MD; Edwin Yau, MD, PhD; Grace K. Dy; Sarabjot Pabla, MSc, PhD, BS; Sean T. Glenn, PhD; Carl D. Morrison, MD, DVM; Daniel J. George, MD; Tian Zhang, MD; Jeffrey M. Clarke, MD | Biomarkers; Checkpoint blockade; Solid tumors; Tumor microenvironment |
| P147 | Quantitative assessment of co-expression of PD-L1 and CMTM6 in the tumor microenvironment in non-small cell lung cancer (NSCLC) patients treated with PD-1 pathway blockade | Jon Zugazagoitia, MD, PhD; Fahad S. Shabbir, MD; Yuting Liu, PhD candidate; Brian S. Henick, MD; Scott N. Gettinger, MD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD; David L. Rimm, MD, PhD; | Biomarkers; Checkpoint blockade; Tumor microenvironment; Tumor stroma |
| O1 | Identification and profiling of neoantigen-specific T cells in NSCL cancer patients treated with atezolizumab | Michael Fehlings; Suchit Jhunjhunwala, BS, PhD; Marcin Kowanetz, Ph.D.; Bill O'Gorman; Priti S. Hegde, PhD; Jessica Li, Master of Science; Hermi Sumatoh; Boon Heng Lee; Alessandra Nardin, DVM; Leesun Kim; Susan Flynn; Marcus Ballinger, PhD; Evan W. Newell, PhD; Mahesh Yadav, PhD; | Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Neoantigens; T cell; Tumor antigens |
| O2 | Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostate hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations | George A. Dominguez, PhD; John Roop; Alex Polo; Anthony J. Campisi, B.S.; Dmitry I. Gabrilovich, MD, PhD; Amit Kumar, PhD | Bioinformatics; Biomarkers; Clinical study; Granulocyte; Immune monitoring; Myeloid cells; MDSC; Solid tumors |
| O3 | Anti-tumor immune responses in metastatic breast cancer exceptional responder patients | Alusha A. Mamchak, PhD; Ngan A. Nguyen, PhD; Danhui Zhang, MD PhD; Felix Chu, MS; Mike Harbell, BS; Beatriz Millare, BS; Kevin S. Williamson; Xiaomu Chen; Xiaobin Tang; Shuwei Jiang; Dongkyoon Kim, BS PhD; Nicole Hasser; Sarah Hippely; Maren K. Levin; Amy Manning-Bog, PhD; Jeff DeFalco; William H. Robinson, MD, PhD; Daniel Emerling, PhD; Norman M. Greenberg, PhD; Guy Cavet, PhD; William H. Robinson, MD, PhD; Joyce O’Shaughnessy, MD; | Antibody; B cell; Bioinformatics; Biomarkers; Checkpoint blockade; Chemotherapy; Immune monitoring; Solid tumors; Tumor antigens |
| O4 | Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma | Adi Diab, MD; Scott Tykodi; Brendan D. Curti, MD; Daniel C. Cho, MD; Michael K. Wong, MD PhD FRCPC; Igor Puzanov, MD, MSCI, FACP; Karl D. Lewis, MD; Michele Maio, MD, PhD; Gregory A. Daniels, MD, PhD; Alexander I. Spira, MD, PhD, FACP; Mary A. Tagliaferri, MD; Alison L. Hannah, MD; Wendy Clemens, PhD; Michael Imperiale; Chantale Bernatchez; Cara Haymaker, PhD; Salah Eddine Bentebibel; Jonathan Zalevsky, PhD; Ute Hoch, PhD; Christie Fanton, PhD; Ahsan N. Rizwan, MPharm, PhD; Sandra Aung, PhD; Fiore Cattaruzza; Ernesto Iaccucci; Dariusz Sawka; Mehmet A. Bilen, MD; Paul Lorigan; Giovanni Grignani; James Larkin, MD; Sekwon Jang, MD; Ewa Kalinka-Warzocha, PhD, MD; Mario Sznol, MD; Michael E. Hurwitz, MD, PhD | Checkpoint blockade; Clinical trial; Cytokine; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O5 | B-cells and tertiary lymphoid structures (TLS) predict response to immune checkpoint blockade (ICB) | Sangeetha M. Reddy, MD, MSci; Beth Helmink, MD PhD; Jianjun Gao, MD PhD; Shaojun Zhang, PhD; Keren Yizhak; Moshe Sade-Feldman; Jorge M. Blando, DVM; Guangchun Han; Vancheswaran Gopalakrishnan, MPH, PhD; Hao Zhao; Wenbin Liu; Hussein A. Tawbi, MD, PhD; Rodabe N. Amaria, MD; Michael Davies, MD, PhD; Patrick Hwu, MD; Jeffrey E. Lee, MD; Jeffrey E. Gershenwald, MD; Scott Woodman; Elizabeth Burton; Lauren E. Haydu, MS, BChe, MIPH; Alexander J. Lazar, MD, PhD; Courtney Hudgens, MS; Alexandria P. Cogdill, MEng; Oscar Krijgsman, PhD; Elisa A. Rozeman, MD; Daniel Peeper, PhD; Christian U. Blank, MD; Ton N. Schumacher, PhD; Emily Keung; Pierre-Olivier Gaudreau; Alexandre Reuben; Christine N. Spencer, PhD; Lisa H. Butterfield, PhD; James P. Allison, PhD; Michael T. Tetzlaff, MD PhD; Florent Petitprez, MS; Wolf Herman Fridman, MD, PhD; Catherine Sautes-Fridman, PhD; Nir Hacohen, PhD; Padmanee Sharma, MD, PhD; Linghua Wang, PhD; Jennifer A. Wargo, MD, MMSc | B cell; Checkpoint blockade; Gene expression; Immune monitoring; Solid tumors; Tumor microenvironment |
| O6 | Comparison of biomarker assay modalities in anti-PD-(L)1 monotherapy: a meta-analysis | Steve Lu, B.S.; Ludmila Danilova, PhD; David L. Rimm, MD, PhD; Clifford C. Hoyt, MS; Matthew Hellmann, MD; Janis M. Taube, MD, MSC | Biomarkers; Checkpoint blockade; Gene expression; Solid tumors; Tumor microenvironment |
